E de Azambuja
Overview
Explore the profile of E de Azambuja including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
57
Citations
2885
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Agostinetto E, Pfeiler G, Hlauschek D, Mayer E, Lambertini M, de Azambuja E, et al.
ESMO Open
. 2025 Jan;
10(1):104096.
PMID: 39754986
Background: Concomitant intake of proton pump inhibitors (PPIs) may create drug-drug interactions, potentially impacting efficacy of anticancer agents. In the phase III PALLAS trial, the addition of palbociclib capsules to...
2.
Fernandez-Martinez A, Fernandez-Martinez A, Tanioka M, Tanioka M, Ahn S, Ahn S, et al.
Ann Oncol
. 2024 Dec;
PMID: 39706338
Background: In human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (EBC), we investigated tumor and immune changes during neoadjuvant treatment and their impact on residual disease (RD) biology...
3.
Lim K, Kamposioras K, Elez E, Haanen J, Hardy C, Murali K, et al.
ESMO Open
. 2024 Oct;
9(10):103634.
PMID: 39461774
Background: Burnout in health care professionals (HCPs) results from exposure to psychosocial risks at work. Left unaddressed, burnout can lead to chronic health problems, increased staff turnover, reduced work hours,...
4.
de Azambuja E, Piccart-Gebhart M, Fielding S, Townend J, Hillman D, Colleoni M, et al.
ESMO Open
. 2024 Oct;
9(11):103938.
PMID: 39418883
Background: Dual anti-human epidermal growth factor receptor 2 (HER2) blockade has improved the outcomes of patients with early and metastatic HER2-positive breast cancer. Here we present the final 10-year analysis...
5.
Agostinetto E, Bruzzone M, Hamy A, Kim H, Chiodi C, Bernstein-Molho R, et al.
ESMO Open
. 2024 Sep;
9(10):103714.
PMID: 39288653
Background: Young women with breast cancer (BC) have an increased chance of carrying germline BRCA pathogenic variants (PVs). Limited data exist on the prognostic impact of tumor histology (i.e. ductal...
6.
Lobo-Martins S, Agostinetto E, de Azambuja E, Gebhart G
Ann Oncol
. 2024 Aug;
35(11):1061-1062.
PMID: 39098453
No abstract available.
7.
Arecco L, Bruzzone M, Bas R, Kim H, Di Meglio A, Bernstein-Molho R, et al.
Ann Oncol
. 2024 Jun;
35(9):792-804.
PMID: 38908482
Background: Hormone receptor expression is a known positive prognostic and predictive factor in breast cancer; however, limited evidence exists on its prognostic impact on prognosis of young patients harboring a...
8.
Pizzamiglio S, Ciniselli C, de Azambuja E, Agbor-Tarh D, Moreno-Aspitia A, Suter T, et al.
Breast Cancer Res Treat
. 2024 Apr;
206(2):285-294.
PMID: 38689174
Purpose: The relevance of cardiotoxicity in the context of HER2-positive breast cancer is likely to increase with increasing patient treatment exposure, number of treatment lines, and prolonged survival. Circulating biomarkers...
9.
Nader-Marta G, Monteforte M, Agostinetto E, Cinquini M, Martins-Branco D, Langouo M, et al.
ESMO Open
. 2024 Mar;
9(3):102390.
PMID: 38460249
Background: The incorporation of circulating tumor DNA (ctDNA) into the management of operable breast cancer (BC) has been hampered by the heterogeneous results from different studies. We aimed to assess...
10.
Arecco L, Blondeaux E, Bruzzone M, Latocca M, Mariamidze E, Begijanashvili S, et al.
ESMO Open
. 2023 Oct;
8(6):102031.
PMID: 37879234
Background: Despite increasing evidence on the safety of pregnancy after anticancer treatments in breast cancer survivors, many physicians and patients remain concerned about a potential risk of pregnancy specifically in...